Japan Lifeline (7575) Q1 2025 earnings summary

Executive summary

• Achieved record-high quarterly net sales of ¥14,010 million, up 8.2% year-over-year, with both sales and profit reaching new highs, driven by strong growth in EP/ablation and neurovascular products.

• Operating profit grew 0.6% to ¥3,194 million and net profit rose 0.4% to ¥2,340 million, despite temporary cost increases and reimbursement revisions.

• Business outperformed initial expectations, supported by a 10% increase in atrial fibrillation cases and successful new product launches.

• Core product group and new business areas drove significant growth, with new areas expanding 75% year-over-year.

• Comprehensive income increased to ¥2,519 million (+3.4% YoY).

Financial highlights

• Gross profit increased 8.8% year-over-year to ¥8,583 million, with gross margin improving to 61.3%.

• SG&A expenses rose 14.4% due to one-time costs, but strong sales offset the impact.

• EPS increased to ¥31.95 from ¥30.03 year-over-year.

• Third-party product sales grew 12% year-over-year, outpacing in-house product growth of 5%.

• Ordinary profit was ¥3,215 million (−0.9% YoY).

Outlook and guidance

• Q1 net sales achieved 25.9% of full-year guidance and 52.7% of first-half guidance, indicating strong progress.

• Full-year guidance: net sales ¥54,000 million (+5.1%), operating profit ¥11,200 million (+2.8%), net profit ¥8,000 million (+6.4%), EPS ¥113.58.

• Expect continued growth in core and new areas, with reimbursement cuts and competition factored into forecasts.

• Favorable business conditions expected to continue, but no change to guidance as of now.